Profile data is unavailable for this security.
About the company
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
- Revenue in USD (TTM)0.00
- Net income in USD-209.36m
- Incorporated2005
- Employees112.00
- LocationSyndax Pharmaceuticals Inc35 Gatehouse Drive, Building D, Floor 3WALTHAM 02451United StatesUSA
- Phone+1 (781) 419-1400
- Fax+1 (781) 419-1420
- Websitehttps://syndax.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inhibrx Inc | 1.80m | -241.36m | 1.62bn | 166.00 | -- | 37.12 | -- | 897.56 | -5.03 | -5.03 | 0.0382 | 0.9184 | 0.006 | -- | 3.53 | 10,843.37 | -80.07 | -77.06 | -93.12 | -93.91 | -- | -- | -13,318.17 | -1,590.91 | -- | -11.00 | 0.8263 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Myriad Genetics, Inc. | 753.20m | -263.30m | 1.63bn | 2.70k | -- | 2.06 | -- | 2.16 | -3.20 | -3.20 | 9.09 | 8.71 | 0.6423 | 11.22 | 6.98 | 278,963.00 | -22.45 | -- | -25.66 | -- | 68.64 | -- | -34.96 | -- | 1.87 | -342.25 | 0.0469 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| Harmony Biosciences Holdings Inc | 582.02m | 128.85m | 1.64bn | 246.00 | 13.57 | 3.52 | 10.72 | 2.82 | 2.13 | 2.13 | 9.64 | 8.23 | 0.7837 | 25.10 | 9.03 | 2,365,943.00 | 17.35 | 7.46 | 20.74 | 9.08 | 79.17 | 80.58 | 22.14 | 10.46 | 2.72 | 21.27 | 0.293 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Catalyst Pharmaceuticals Inc | 398.20m | 71.41m | 1.73bn | 167.00 | 24.10 | 4.05 | 16.61 | 4.35 | 0.6092 | 0.6092 | 3.56 | 3.62 | 0.9417 | 4.63 | 12.45 | 2,384,455.00 | 16.89 | 25.42 | 20.06 | 29.81 | 86.95 | 85.63 | 17.93 | 30.87 | 2.68 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Syndax Pharmaceuticals Inc | 0.00 | -209.36m | 1.75bn | 112.00 | -- | 3.15 | -- | -- | -2.96 | -2.96 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -37.72 | -27.90 | -40.93 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
| Beam Therapeutics Inc | 377.71m | -132.53m | 1.76bn | 436.00 | -- | 1.80 | -- | 4.67 | -1.87 | -1.87 | 4.90 | 12.02 | 0.2697 | -- | -- | 866,305.10 | -9.46 | -24.54 | -11.17 | -29.26 | -- | -- | -35.09 | -211.96 | -- | -- | 0.0005 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Agios Pharmaceuticals Inc | 26.82m | -352.09m | 1.78bn | 383.00 | -- | 2.18 | -- | 66.35 | -6.33 | -6.33 | 0.482 | 14.50 | 0.0247 | 0.209 | 10.69 | 70,033.95 | -32.36 | -29.54 | -34.43 | -31.88 | 89.26 | -- | -1,312.64 | -3,826.10 | 11.99 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Twist Bioscience Corp | 262.36m | -205.80m | 1.80bn | 919.00 | -- | 3.04 | -- | 6.85 | -3.60 | -3.60 | 4.59 | 10.21 | 0.3194 | 4.47 | 7.04 | 285,488.60 | -25.06 | -30.50 | -27.56 | -33.84 | 35.79 | 36.02 | -78.44 | -113.33 | 5.51 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| Fusion Pharmaceuticals Inc | 2.07m | -94.90m | 1.82bn | 113.00 | -- | 7.67 | -- | 878.20 | -1.47 | -1.47 | 0.0315 | 2.79 | 0.0082 | -- | 60.82 | 18,300.88 | -37.59 | -35.45 | -40.07 | -38.55 | -- | -- | -4,588.83 | -7,206.24 | -- | -- | 0.1352 | -- | 41.55 | -- | -8.32 | -- | 28.21 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -89.62m | 1.82bn | 93.00 | -- | 3.99 | -- | -- | -2.51 | -2.51 | 0.00 | 9.76 | 0.00 | -- | -- | 0.00 | -30.91 | -- | -33.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Amneal Pharmaceuticals Inc | 2.39bn | -83.99m | 1.82bn | 7.70k | -- | 136.81 | 10.08 | 0.7606 | -0.3116 | -0.3116 | 13.46 | 0.0431 | 0.6583 | 2.83 | 3.53 | 310,858.10 | -1.34 | -4.80 | -1.70 | -5.93 | 34.28 | 34.76 | -2.04 | -9.00 | 0.9408 | 1.14 | 0.9778 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Sana Biotechnology Inc | 0.00 | -283.26m | 1.86bn | 328.00 | -- | 5.85 | -- | -- | -1.46 | -1.46 | 0.00 | 1.45 | 0.00 | -- | -- | 0.00 | -40.81 | -38.99 | -46.74 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
| Recursion Pharmaceuticals Inc | 44.58m | -328.07m | 1.86bn | 500.00 | -- | 3.96 | -- | 41.78 | -1.57 | -1.57 | 0.2145 | 1.98 | 0.0658 | -- | 15.25 | 89,150.00 | -48.42 | -- | -56.49 | -- | 4.46 | -- | -735.99 | -- | -- | -- | 0.0025 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
Data as of Apr 25 2024. Currency figures normalised to Syndax Pharmaceuticals Inc's reporting currency: US Dollar USD
53.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 31 Dec 2023 | 7.59m | 8.93% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 5.73m | 6.75% |
| Kynam Capital Management LPas of 31 Dec 2023 | 5.66m | 6.66% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 5.02m | 5.90% |
| Avoro Capital Advisor LLCas of 31 Dec 2023 | 4.22m | 4.97% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 4.16m | 4.89% |
| Avidity Partners Management LPas of 31 Dec 2023 | 3.95m | 4.65% |
| Eversept Partners LPas of 31 Dec 2023 | 3.38m | 3.98% |
| Point72 Asset Management LPas of 31 Dec 2023 | 2.83m | 3.34% |
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 2.71m | 3.19% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
